BK21 FOUR Team and Integrated Research Institute for Drug Development, College of Pharmacy, Dongguk University-Seoul, Goyang, 10326, Korea.
Int J Nanomedicine. 2021 Nov 12;16:7535-7556. doi: 10.2147/IJN.S337427. eCollection 2021.
Probiotics have demonstrated their high potential to treat and/or prevent various diseases including neurodegenerative disorders, cancers, cardiovascular diseases, and inflammatory diseases. Probiotics are also effective against multidrug-resistant pathogens and help maintain a balanced gut microbiota ecosystem. Accordingly, the global market of probiotics is growing rapidly, and research efforts to develop probiotics into therapeutic adjuvants are gaining momentum. However, because probiotics are living microorganisms, many biological and biopharmaceutical barriers limit their clinical application. Probiotics may lose their activity in the harsh gastric conditions of the stomach or in the presence of bile salts. Moreover, they easily lose their viability under thermal or oxidative stress during their preparation and storage. Therefore, stable formulations of probiotics are required to overcome the various physicochemical, biopharmaceutical, and biological barriers and to maximize their therapeutic effectiveness and clinical applicability. This review provides an overview of the pharmaceutical applications of probiotics and covers recent formulation approaches to optimize the delivery of probiotics with particular emphasis on various dosage forms and formulation technologies.
益生菌已被证明具有治疗和/或预防多种疾病的巨大潜力,包括神经退行性疾病、癌症、心血管疾病和炎症性疾病。益生菌还可以有效对抗多药耐药病原体,并有助于维持肠道微生物群落的平衡。因此,益生菌的全球市场正在迅速增长,将益生菌开发为治疗佐剂的研究工作也在不断增加。然而,由于益生菌是活的微生物,许多生物和生物制药障碍限制了它们的临床应用。益生菌在胃的恶劣环境或胆汁盐存在的情况下可能会失去活性。此外,在制备和储存过程中,它们很容易在热或氧化应激下失去活力。因此,需要稳定的益生菌配方来克服各种物理化学、生物制药和生物学障碍,最大限度地提高其治疗效果和临床适用性。本综述概述了益生菌的药物应用,并介绍了最近优化益生菌递送的制剂方法,特别强调了各种剂型和制剂技术。